Stock Scorer

Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics, Inc. reported revenue of 1.5M USD for the quarter ending 30 June 2026, up 504.9% from 244K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.5M +504.9%
Operating Income Q2 '26 · ending 30 June 2026 -13.3M —
Net Income Q2 '26 · ending 30 June 2026 -13M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -14.7M —
Free Cash Flow Q4 '22 · ending 31 December 2022 -9.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 43M +39.9%
EPS Q2 '26 · ending 30 June 2026 -1.66 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20262026-03-31 1.3M-72.1M-69.7M—
20252025-03-31 486K-56M-51.4M—
20242024-03-31 1.1M-33M-29.4M-25.8M
20232023-03-31 -227K-59.3M-59.2M-50.2M
20222022-03-31 1.1M-47.8M-47.8M-45.5M
20212021-03-31 1.1M-17.9M-17.9M-12.3M
20202020-03-31 0-20.8M-20.8M-15.8M
20182018-03-31 0-14.2M-14.3M-9.1M
20172017-03-31 1.2M-10.2M-10.3M-7.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q1 '272026-06-301.5M
Q4 '262026-03-31465K
Q3 '262025-12-31303K
Q2 '262025-09-30258K
Q1 '262025-06-30244K
Q4 '252025-03-31-15K
Q3 '252024-12-31234K
Q2 '252024-09-30183K
Q1 '252024-06-3084K
Q4 '242024-03-31197K
Q3 '242023-12-31411K
Q2 '242023-09-30278K
Q1 '242023-06-30177K
Q4 '232023-03-31176K
Q3 '232022-12-31180K
Q2 '232022-09-30-893K
Q1 '232022-06-30310.1K
Q4 '222022-03-3138.9K
Q3 '222021-12-31357.9K
Q2 '222021-09-30358K

Operating Income Quarterly

PeriodEndingOperating Income
Q1 '272026-06-30-13.3M
Q4 '262026-03-31-16.7M
Q3 '262025-12-31-19.5M
Q2 '262025-09-30-20.1M
Q1 '262025-06-30-15.8M
Q4 '252025-03-31-14.5M
Q3 '252024-12-31-15.1M
Q2 '252024-09-30-14.2M
Q1 '252024-06-30-12.1M
Q4 '242024-03-31-11.4M
Q3 '242023-12-31-7.9M
Q2 '242023-09-30-6.8M
Q1 '242023-06-30-7M
Q4 '232023-03-31-12.2M
Q3 '232022-12-31-9.8M
Q2 '232022-09-30-17.5M
Q1 '232022-06-30-19.8M
Q4 '222022-03-31-16.7M
Q3 '222021-12-31-10.5M
Q2 '222021-09-30-12.8M

Net Income Quarterly

PeriodEndingNet Income
Q1 '272026-06-30-13M
Q4 '262026-03-31-16.3M
Q3 '262025-12-31-18.9M
Q2 '262025-09-30-19.4M
Q1 '262025-06-30-15.1M
Q4 '252025-03-31-13.6M
Q3 '252024-12-31-14.1M
Q2 '252024-09-30-13M
Q1 '252024-06-30-10.7M
Q4 '242024-03-31-9.5M
Q3 '242023-12-31-6.3M
Q2 '242023-09-30-6.6M
Q1 '242023-06-30-6.9M
Q4 '232023-03-31-12.2M
Q3 '232022-12-31-9.8M
Q2 '232022-09-30-17.5M
Q1 '232022-06-30-19.8M
Q4 '222022-03-31-16.7M
Q3 '222021-12-31-10.5M
Q2 '222021-09-30-12.8M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q1 '272026-06-30-14.7M
Q4 '262026-03-31-16.2M
Q3 '262025-12-31-17.6M
Q2 '262025-09-30-13.8M
Q1 '262025-06-30-18.8M
Q4 '252025-03-31-10.1M
Q3 '252024-12-31-10.3M
Q2 '252024-09-30-10.9M
Q1 '252024-06-30-10.9M
Q4 '242024-03-31-7M
Q3 '242023-12-31-4.7M
Q2 '242023-09-30-6.2M
Q1 '242023-06-30-7.9M
Q4 '232023-03-31-7.5M
Q3 '232022-12-31-9.9M
Q2 '232022-09-30-16.3M
Q1 '232022-06-30-16M
Q4 '222022-03-31-15.6M
Q3 '222021-12-31-12M
Q2 '222021-09-30-11.4M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q3 '232022-12-31-9.9M
Q2 '232022-09-30-16.4M
Q1 '232022-06-30-16.1M
Q4 '222022-03-31-15.6M
Q3 '222021-12-31-12M
Q2 '222021-09-30-11.5M
Q1 '222021-06-30-6.3M
Q4 '212021-03-31-5.3M
Q1 '212020-06-30-2.8M
Q4 '192019-03-31-3.7M
Q3 '192018-12-31-3.9M
Q4 '182018-03-31-2.6M
Q3 '182017-12-31-2.4M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q1 '272026-06-3043M
Q3 '262025-12-3142.2M
Q2 '262025-09-3035.7M
Q1 '262025-06-3031.9M
Q3 '252024-12-3130.7M
Q2 '252024-09-3030.6M
Q1 '252024-06-3030.6M
Q3 '242023-12-3129.4M
Q2 '242023-09-3010M
Q1 '242023-06-307.3M
Q4 '232023-03-317.2M
Q3 '232022-12-316.9M
Q2 '232022-09-306.9M
Q1 '232022-06-306.9M
Q4 '222022-03-316.9M
Q3 '222021-12-31202.3M
Q2 '222021-09-30193.2M
Q1 '222021-06-30189.9M
Q3 '162015-12-311.8M
Q2 '162015-09-301.6M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '272026-06-30-1.66
Q4 '262026-03-31-1.83
Q3 '262025-12-31-1.90
Q2 '262025-09-30-1.91
Q1 '262025-06-30-1.79
Q4 '252025-03-31-1.67
Q3 '252024-12-31-1.48
Q2 '252024-09-30-1.24
Q1 '252024-06-30-1.48
Q4 '242024-03-31-2.07
Q3 '242023-12-31-3.53
Q2 '242023-09-30-4.73
Q1 '242023-06-30-6.61
Q4 '232023-03-31-8.54
Q3 '232022-12-31-9.25
Q2 '232022-09-30-7.88
Q1 '232022-06-30-5.41
Q4 '222022-03-31-2.58
Q3 '222021-12-31-0.36
Q2 '222021-09-30-0.38